<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00162916</url>
  </required_header>
  <id_info>
    <org_study_id>rapoportm-ONF2004-abi-dep-03</org_study_id>
    <nct_id>NCT00162916</nct_id>
  </id_info>
  <brief_title>Antidepressant Maintenance in Traumatic Brain Injury</brief_title>
  <official_title>A Randomized Controlled Trial of Antidepressant Maintenance for Major Depression Following Mild Traumatic Brain Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ontario Neurotrauma Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ontario Neurotrauma Foundation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to explore to what extent continuing the antidepressant&#xD;
      medication citalopram (Celexa), after depression has responded to treatment, helps prevent&#xD;
      the return of depressive symptoms in patients with recent traumatic brain injury (TBI).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      While antidepressants are effective in treating major depression following TBI, there is a&#xD;
      lack of certainty as to how long antidepressants must be continued following improvement of&#xD;
      symptoms. Many studies published in the last decade strongly show that antidepressants&#xD;
      prevent relapse in patients with major depression in the absence of traumatic brain injury&#xD;
      (TBI). However, is it unknown as to whether this is the case following TBI. The aim of this&#xD;
      study is to determine whether being on an antidepressant for a year reduces the risk of&#xD;
      relapse of depression.&#xD;
&#xD;
      Patients diagnosed with major depression following mild TBI will be treated for ten weeks&#xD;
      with the antidepressant drug citalopram. Those who respond, meaning that the symptoms of&#xD;
      depression have lessened significantly, will be randomly assigned to either continue taking&#xD;
      the citalopram for one year or to take a placebo for one year. Every four weeks, for an&#xD;
      additional forty weeks, patients will be assessed for relapse of depression. This study will&#xD;
      have a double-blind design, meaning that neither patient nor clinician know whether&#xD;
      citalopram or placebo is being administered.&#xD;
&#xD;
      The primary outcome of interest will be a comparison of the percentage of patients who have a&#xD;
      recurrence of major depression while continued on citalopram compared with those who were&#xD;
      switched to placebo after the acute phase. Recurrence will be defined as meeting Diagnostic&#xD;
      and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) criteria for major&#xD;
      depression and a Hamilton Depression Scale (HAM-D) score of &gt; 16. Or meeting DSM-IV criteria&#xD;
      for major depression and having a Clinical Global Impression (CGI) severity score of &gt;= 4 and&#xD;
      a CGI illness score of &gt;= 3. The HAM-D and CGI will be administered every four weeks for&#xD;
      forty weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>May 2005</start_date>
  <completion_date type="Anticipated">October 2008</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>recurrence of major depression by administering the Hamilton Depression Rating Scale (HAM-D) and Clinical Global Impressions Scale (CGI) every 4 weeks for 40 weeks</measure>
    <time_frame>40 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>general cognitive function at baseline, 10 weeks and on termination of the trial</measure>
    <time_frame>40 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>list of adverse drug events at baseline, 10 weeks and on termination of the trial</measure>
    <time_frame>40 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>citalopram</intervention_name>
    <description>20mg or 40mg, once daily, for 40 weeks</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Celexa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Cornstarch</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  TBI within the last year (this is consistent with clinic population)&#xD;
&#xD;
          -  Mild TBI&#xD;
&#xD;
          -  Written, informed consent&#xD;
&#xD;
          -  Diagnosis of major depressive episode using the depression module of the Structured&#xD;
             Clinical Interview for DSM-IV Axis I disorders (SCID-IV), and baseline 17-item&#xD;
             Hamilton Depression (HAM-D) Rating Scale score of 16 and above (prior to selective&#xD;
             serotonin reuptake inhibitor [SSRI] treatment)&#xD;
&#xD;
          -  Response to citalopram 20 or 40mg/d, as defined as a reduction in baseline HAM-D of &gt;=&#xD;
             50%, and HAM-D score of 10 or below; or response to citalopram defined as not meeting&#xD;
             DSM-IV criteria for major depression and Clinical Global Impression - severity of&#xD;
             mildly ill, borderline ill, or normal and a Clinical Global Impression - improvement&#xD;
             of much improved or very much improved impression.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior TBI or other focal brain disease (e.g., stroke, tumour)&#xD;
&#xD;
          -  Significant acute medical illness including: drug overdose; severely disturbed liver,&#xD;
             kidney, lung or heart function; anemia; hypothyroidism; uncontrolled diabetes;&#xD;
             Parkinson's disease; Huntington's chorea; progressive supranuclear palsy; brain tumor;&#xD;
             subdural hematoma; or multiple sclerosis.&#xD;
&#xD;
          -  Current alcohol or substance abuse&#xD;
&#xD;
          -  A brain computed tomographic (CT) scan revealing focal lesions that could not be&#xD;
             interpreted as consistent with TBI&#xD;
&#xD;
          -  Presence of premorbid psychiatric diagnosis of schizophrenia, dementia or bipolar&#xD;
             disorder&#xD;
&#xD;
          -  Prior episode of major depression in two years prior to TBI, based on SCID-IV&#xD;
             interview&#xD;
&#xD;
          -  Prior treatment with citalopram or contraindications to receiving treatment with&#xD;
             citalopram&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark J Rapoport, MD, FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sunnybrook Health Sciences Centre, University of Toronto</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://www.onf.org</url>
    <description>Ontario Neurotrauma Foundation - funding agency for this study</description>
  </link>
  <verification_date>June 2008</verification_date>
  <study_first_submitted>September 10, 2005</study_first_submitted>
  <study_first_submitted_qc>September 10, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 13, 2005</study_first_posted>
  <last_update_submitted>June 3, 2008</last_update_submitted>
  <last_update_submitted_qc>June 3, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 4, 2008</last_update_posted>
  <responsible_party>
    <name_title>Mark J Rapoport</name_title>
    <organization>Sunnybrook Health Sciences Centre</organization>
  </responsible_party>
  <keyword>Traumatic Brain Injury</keyword>
  <keyword>Depression</keyword>
  <keyword>Antidepressant medication</keyword>
  <keyword>Double-Blind Study</keyword>
  <keyword>Brain Injuries</keyword>
  <keyword>Antidepressive Agents</keyword>
  <keyword>Citalopram</keyword>
  <keyword>Double-Blind Method</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Brain Injuries, Traumatic</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citalopram</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

